Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Income (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Operating Income for 8 consecutive years, with -$31.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 6.25% year-over-year to -$31.3 million, compared with a TTM value of -$76.3 million through Dec 2025, up 20.29%, and an annual FY2025 reading of -$76.3 million, up 20.29% over the prior year.
  • Operating Income was -$31.3 million for Q4 2025 at Arcturus Therapeutics Holdings, down from -$16.5 million in the prior quarter.
  • Across five years, Operating Income topped out at $121.5 million in Q4 2022 and bottomed at -$57.7 million in Q1 2021.
  • Average Operating Income over 5 years is -$22.0 million, with a median of -$26.3 million recorded in 2022.
  • The sharpest move saw Operating Income crashed 509.45% in 2021, then surged 422.62% in 2022.
  • Year by year, Operating Income stood at -$37.6 million in 2021, then soared by 422.62% to $121.5 million in 2022, then tumbled by 115.04% to -$18.3 million in 2023, then crashed by 82.76% to -$33.4 million in 2024, then rose by 6.25% to -$31.3 million in 2025.
  • Business Quant data shows Operating Income for ARCT at -$31.3 million in Q4 2025, -$16.5 million in Q3 2025, and -$11.6 million in Q2 2025.